Deerfield Management
345 Park Avenue SouthNew York, NY 10010
Website: deerfield.com
Firm Size
- Assets Under Management (AUM):$16.1 Billion
- Number of Funds:11
- Employees:178
- Firm Type:Hedge Fund
Description
Deerfield Management Company is a New York-based investment management firm that specializes in the healthcare industry. Founded in 1994, the company manages both long and short-term investments in public and private healthcare companies. Headquartered in New York City, Deerfield Management Company has established a strong reputation for its deep expertise in the healthcare sector. The firm's investment strategies range from traditional long-only portfolios to more focused, event-driven strategies. Deerfield Management has a team of experienced professionals who perform rigorous research and analysis to identify attractive investment opportunities in the healthcare industry. They leverage their extensive network and industry knowledge to make informed investment decisions. In addition to its investment activities, Deerfield Management is also actively involved in promoting innovation in healthcare. The company has established various initiatives, including the Deerfield Institute, which conducts research on healthcare topics to drive improvements in patient outcomes. Overall, Deerfield Management Company is a prominent investment management firm based in New York City, focused on the healthcare sector. With its deep industry knowledge and extensive network, the company is well-positioned to generate attractive returns for its investors.Latest News
Powered by
Jun 17, 2024: Elion Therapeutics Closes $81 Million Series B Funding Round Led by Deerfield Management and AMR Action Fund
Elion Therapeutics ("Elion", formerly Sfunga Therapeutics), a biotechnology company dedicated to transforming the treatment of life-threatening invasive fungal infections (IFIs), announced today it has closed a $81 million Series B funding round led by Deerfield Management (" Deerfield ") and the AMR Action Fund. Additional investors include Illinois Ventures.
Jun 11, 2024: Leo Cancer Care to Use Series C Financing to Grow Global Footprint
Leo Cancer Care is delighted to announce that it has secured funding to advance the company to the next stage of its global ambitions for upright radiation therapy.
Jun 05, 2024: Deerfield Management Welcomes Frank Nestle, MD, FMedSci, as Partner and Chief Executive Officer of Therapeutic Discovery and Development
Deerfield Management is pleased to welcome Dr. Frank Nestle , M.D., FMedSci, as Partner on the Therapeutics team and Chief Executive Officer of the firm's therapeutic discovery and development operations.
Jun 03, 2024: Cure® Unveils US Biotech Industry Benchmark Report 2024: Dark Days of 2023 are Over
Cure . ® , a healthcare innovation campus in New York City , today unveiled results from Ready, Set, Growth! Biotech Benchmark Report 2024 at the 2024 BIO International Convention in San Diego, CA. Cure conducted this highly anticipated assessment of the biotech industry in partnership with the Deerfield Institute , a division of Deerfield Management Company. The stakeholders surveyed included company founders and CEOs, managing directors, investors, scientists, and more.
May 06, 2024: Deerfield Management and Deerfield Foundation Announce Second Annual AML Summit and Recipients of American Society of Hematology (ASH) Peter Steelman Scholar Award
Deerfield Management and the Deerfield Foundation announced today they will honor the 2023-2024 recipients of the American Society of Hematology (ASH) Peter Steelman Scholar Award at the second annual Acute Myeloid Leukemia (AML) Summit. The AML Summit convenes industry experts, leaders, and partners across healthcare to further advance research on this cancer of the bone marrow and blood.
Apr 17, 2024: Genscience and Deerfield Management Announce Nature Publication Reporting Positive Impact of Genetic Evidence to Aid Discovery of More Effective Drug Targets
Genscience LLC , a company applying genetic evidence and proprietary platforms for drug discovery and development and an affiliate of Deerfield Management Company (" Deerfield "), a healthcare investment firm, today announced a new study that shows incorporating genetic evidence into drug design significantly increases the probability of successful development by up to 2.6 times compared to when genetic evidence is absent. The new study appeared in the April 17, 2024 issue of the peer-reviewed journal Nature .¹ The study also documents new findings regarding how different characteristics of genetic evidence impact drug development success.
Apr 09, 2024: CURE OPENS XSEED AWARD APPLICATIONS TO SUPPORT UNDERFUNDED AND UNDERREPRESENTED NYC LIFE SCIENCE STARTUPS WITH UP TO $500,000
Cure ®, a healthcare innovation campus in New York City, has opened applications to the XSeed Award, an annual competitive program designed to disrupt the status quo by supporting traditionally underfunded and underrepresented minority- and women-led life science and healthcare startups working on drug development in New York City . Deerfield Management, a New York City -based healthcare investment firm, founded and supports the XSeed Award.
Feb 26, 2024: Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases
Neomorph, Inc. today announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and commercialize molecular glue degraders. Neomorph, a biotechnology company solving critical problems in human health through the discovery of novel therapeutics against 'undruggable' targets, was founded in 2020 and is venture backed by Deerfield Management Company.
Feb 01, 2024: Cohere Health Raises $50 Million in Equity to Meet Increased Demand for AI-Driven Transformation of Prior Authorization Process
Cohere Health , a recognized leader in clinical intelligence and prior authorization automation, announced it has closed $50 million in additional equity funding. The funding was led by Deerfield Management, with participation from Define Ventures, Flare Capital Partners, Longitude Capital, and Polaris Partners, and brings the total raised by Cohere to $106 million . The latest round of funding will fuel the company's expansion to meet the increasing demand for Cohere's intelligent prior authorization platform.
Jan 16, 2024: Washington University and Deerfield Management Launch VeritaScience to Drive Drug Discovery
Washington University in St. Louis and Deerfield Management (" Deerfield "), a healthcare investment firm, today announced the launch of VeritaScience, a new private R&D collaboration designed to advance the discovery, clinical development and commercialization of promising therapeutic and diagnostic candidates with potential to benefit human health.
Dec 11, 2023: Deerfield Foundation Awards More Than $1.4 Million to Improve Health, Accelerate Innovation and Promote Equity
Deerfield Foundation ("Deerfield"), the philanthropic affiliate of Deerfield Management Company, a healthcare investment firm, today announced the awarding of $1.497 million to support 13 grantee not-for-profit organizations in seven countries in their 2024 healthcare initiatives to benefit children and their families from underserved communities.
Nov 08, 2023: Sfunga Therapeutics and Deerfield Management Announce Publication on Novel Antifungal SF001 in Nature
Sfunga Therapeutics ("Sfunga"), a biotechnology company, and Deerfield Management Company (" Deerfield "), a healthcare investment firm, today announced the publication of data on a novel antifungal molecule AM2-19 in the scientific journal Nature . [1] AM2-19 is a derivative of amphotericin (AmB), rationally designed to mitigate toxicities and optimize antifungal activity. AM2-19, formulated as the development candidate, SF001, received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.S. Food and Drug Administration (FDA) in 2023, and is in Phase 1 clinical development.
Sep 25, 2023: Adela Announces $48 Million in Financing and Leadership Addition to Advance Tissue-Agnostic Minimal Residual Disease (MRD) Monitoring Product Portfolio Based on Genome-Wide Methylome Approach
Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a genome-wide methylome approach, announced today the closing of $48 million in financing. In addition, the company announced that Lisa Alderson will join Adela as interim Chief Executive Officer (CEO), succeeding Dr. Scott Bratman . Dr. Bratman will continue to serve as a member of Adela's Board of Directors and as President.
Jun 13, 2023: LSI USA Emerging Medtech Summit Returns to Dana Point March 18, 2024
LSI, the company behind LSI Emerging Medtech Summits, the partnering events for global leaders building breakthrough healthcare businesses, today announced it will host its next USA Emerging Medtech Summit, LSI USA '24, on March 18 through 22 at the Monarch Beach Resort, Waldorf Astoria in Dana Point, California .
Jun 08, 2023: Deerfield Management and the Deerfield Foundation Announce the Creation of the American Society of Hematology (ASH) Peter Steelman Scholar Award and the First Annual AML Summit to Advance Research for
Deerfield Management and the Deerfield Foundation announced today the creation of the American Society of Hematology (ASH) Peter Steelman Scholar Award and the first Annual AML Summit in honor of former, longtime Deerfield Partner Peter Steelman . Both efforts aim to further advance research for Acute Myeloid Leukemia (AML).